• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Harrow Inc.

    6/20/25 7:22:12 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HROW alert in real time by email
    S-8 1 forms-8.htm S-8

     

    As filed with the Securities and Exchange Commission on June 20, 2025

     

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

     

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    HARROW, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   45-0567010

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

    1A Burton Hills Blvd., Suite 200

    Nashville, Tennessee

      37215
    (Address of Principal Executive Offices)   (Zip Code)

     

    Harrow, Inc. 2025 Incentive Stock and Awards Plan

    (Full title of the plan)

     

     

     

    Mark L. Baum

    Chief Executive Officer

    Harrow, Inc.

    1A Burton Hills Blvd., Suite 200

    Nashville, Tennessee 37215

    Telephone: (615) 733-4730

    (Name, address and telephone number, including area code, of agent for service)

     

     

     

    Copy to:

    James H. Nixon III

    Holland & Knight LLP

    511 Union Street, Suite 2700

    Nashville, Tennessee 37219

    Telephone: (615) 244-6380

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐   Accelerated filer ☒
    Non-accelerated filer ☐   Smaller reporting company ☐
          Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The document(s) containing the information specified in Part I of this Form S-8 will be sent or given to employees as specified by Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”). Such documents need not be filed with the Securities and Exchange Commission (the “SEC”) either as part of this registration statement (this “Registration Statement”) or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II hereof, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

     

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The SEC allows us to “incorporate by reference” information into this Registration Statement, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. The following documents, which have been filed by Harrow, Inc. (the “Registrant”) with the SEC, are incorporated in this Registration Statement by reference:

     

    (a) The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024;

     

    (b) The Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025;

     

    (c) The Registrant’s Current Reports on Form 8-K filed with the SEC on January 21, 2025, June 9, 2025 and June 20, 2025 (other than information furnished pursuant to Item 2.02 or Item 7.01 of the Current Report on Form 8-K, unless expressly stated otherwise therein); and

     

    (d) The description of the Registrant’s common stock contained in the Registrant’s registration statement on Form 8-A, filed with the SEC pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on February 7, 2013 (Reg. No. 001-35814), including any amendments or reports filed for the purpose of updating such descriptions.

     

    All reports and other documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this Registration Statement, but prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such documents.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 4.Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

     

     

     

    Item 6. Indemnification of Directors and Officers.

     

    The Registrant is incorporated under the laws of the State of Delaware. Section 102(b)(7) of the Delaware General Corporation Law (the “DGCL”) allows a corporation to provide in its certificate of incorporation that a director of the corporation will not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except where the director breached the duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. The Registrant’s amended and restated certificate of incorporation provides for this limitation of liability.

     

    Section 145 of the DGCL (“Section 145”) provides that a Delaware corporation may indemnify any person who was, is or is threatened to be made party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person is or was an officer, director, employee or agent of such corporation or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the corporation’s best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his or her conduct was illegal. A Delaware corporation may indemnify any persons who are, were or are threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation by reason of the fact that such person is or was a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit, provided such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the corporation’s best interests, provided that no indemnification is permitted without judicial approval if the officer, director, employee or agent is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense of any action referred to above, the corporation must indemnify him against the expenses which such officer or director has actually and reasonably incurred.

     

    Section 145 further authorizes a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise, against any liability asserted against him or her and incurred by him or her in any such capacity, or arising out of his or her status as such, whether or not the corporation would otherwise have the power to indemnify him or her under Section 145.

     

    The Registrant’s amended and restated bylaws provide that the Registrant must indemnify and hold harmless its directors, officers, employees and agents to the fullest extent authorized by the DGCL and must also pay expenses incurred in defending any such proceeding in advance of its final disposition; provided, that if and to the extent required by the DGCL, the advancement of expenses shall only be made upon delivery of an undertaking, by or on behalf of an indemnified person, to repay all amounts so advanced if it should be determined ultimately that such person is not entitled to be indemnified.

     

    The Registrant entered into indemnification agreements with each of its directors and executive officers. These agreements require the Registrant to indemnify these individuals to the fullest extent permitted under Delaware law against liabilities that may arise by reason of their service to the Registrant, and to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified.

     

    The indemnification rights set forth above shall not be exclusive of any other right which an indemnified person may have or hereafter acquire under any statute, provision of the Registrant’s certificate of incorporation or bylaws, agreement, vote of stockholders or disinterested directors or otherwise.

     

    The Registrant maintains standard policies of insurance that provide coverage (1) to its directors and officers against loss arising from claims made by reason of breach of duty or other wrongful act and (2) to the Registrant with respect to indemnification payments that it may make to such directors and officers.

     

     

     

     

    Item 7.Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

    Exhibit Number   Description
    4.1   Amended and Restated Certificate of Incorporation, as amended (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K of Harrow, Inc. filed with the Securities and Exchange Commission on September 29, 2023).
    4.2   Amended and Restated Bylaws of Harrow, Inc. (incorporated herein by reference to Exhibit 3.2 to the Current Report on Form 8-K of Harrow, Inc. filed with the Securities and Exchange Commission on September 29, 2023).
    5.1*   Opinion of Holland & Knight LLP, with respect to the legality of the shares of common stock being registered hereby.
    23.1*   Consent of Crowe LLP, Independent Registered Public Accounting Firm.
    23.2*   Consent of KMJ Corbin & Company LLP, Independent Registered Public Accounting Firm.
    23.3   Consent of Holland & Knight LLP (included in Exhibit 5.1).
    24   Power of Attorney of certain officers and directors of the Registrant to file future amendments (set forth on the signature page of this registration statement).
    99.1   Harrow, Inc. 2025 Incentive Stock and Awards Plan (incorporated herein by reference to Appendix A to the Registrant’s Definitive Proxy Statement filed with the SEC on April 25, 2025).
    107*   Filing Fee Table.

     

     

    * Filed herewith.

      

    Item 9. Undertakings.

     

    (a) The undersigned registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” or “Calculation of Registration Fee” table, as applicable, in the effective registration statement;

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Nashville, state of Tennessee, on June 20, 2025.

     

      HARROW, INC.
         
      By: /s/ Mark L. Baum
        Mark L. Baum
        Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Mark L. Baum and Andrew R. Boll, and each of them individually, as his or her true and lawful attorney-in-fact and agent, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Mark L. Baum   Chief Executive Officer and Chairman of the Board   June 20, 2025
    Mark L. Baum   (Principal Executive Officer)    
             
    /s/ Andrew R. Boll   Chief Financial Officer and Corporate Secretary   June 20, 2025
    Andrew R. Boll   (Principal Accounting and Financial Officer)    
             
    /s/ Adrienne L. Graves   Director   June 20, 2025
    Adrienne L. Graves        
             
    /s/ Lauren P. Silvernail   Director   June 20, 2025
    Lauren P. Silvernail        
             
    /s/ Perry J. Sternberg   Director   June 20, 2025
    Perry J. Sternberg        

     

     

     

     

    Get the next $HROW alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HROW

    DatePrice TargetRatingAnalyst
    7/11/2025$76.00Overweight
    Cantor Fitzgerald
    6/12/2025$62.00Buy
    BTIG Research
    6/10/2025Outperform
    William Blair
    2/6/2025$57.00Buy
    H.C. Wainwright
    12/4/2024$73.00 → $69.00Buy
    B. Riley Securities
    4/11/2024$24.00Buy
    Craig Hallum
    9/8/2022$17.00Buy
    B. Riley Securities
    10/14/2021$16.00Buy
    B. Riley Securities
    More analyst ratings

    $HROW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in California

    The Montana-based compounder commits to supporting prescribers and patients in wake of competitor's abrupt exit of California market OSRX, Inc., a leading provider of compounded ophthalmic medications, announced that the company remains fully licensed, fully operational and continues to serve the needs of California ophthalmologists and optometrists, following a significant market shift involving a major competitor. According to a Feb. 2, 2026 company disclosure, ImprimisRx – the compounding division of Harrow (NASDAQ:HROW) – voluntarily forfeited its California license on February 1 and agreed to pay an administrative fine of approximately $157,000 as part of a settlement agreement rea

    2/3/26 5:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth

    Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to the Office-Based Setting Underway, and Doubling TRIESENCE® Commercial Footprint in the Surgical-Based Setting is Proceeding OneHarrow Initiative is Launched to Unify Branding under Harrow Patrick W. Sullivan Promoted to Serve as Harrow's Chief Commercial Officer MELT-300 and MELT-210 Programs on Track for New Drug Application Filings Harrow's ImprimisRx Settles Pending Regulatory Matters with the California Board of Pharmacy NASHVILLE, Tenn., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today reaffirmed its

    2/2/26 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow to Present at Two Investor Conferences in December

    NASHVILLE, Tenn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following two investor conferences in December: BTIG 5th Annual Ophthalmology Day (Virtual)Format: Fireside chatDate/Time: Monday, December 1, 2025, at 8:30 AM EST Piper Sandler 37th Annual Healthcare Conference (New York, NY)Format: Fireside chatDate/Time: Tuesday, December 2, 2025, at 3:00 PM EST The fireside chat at Piper Sandler will be webcast live and can be found on the Event's page on the Company's website. A replay will be available for approximately 90 days following the

    11/24/25 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    SEC Filings

    View All

    Harrow Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - HARROW, INC. (0001360214) (Filer)

    2/2/26 7:30:56 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - HARROW, INC. (0001360214) (Filer)

    11/18/25 8:00:40 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Harrow Inc.

    10-Q - HARROW, INC. (0001360214) (Filer)

    11/10/25 5:16:28 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CHIEF COMMERCIAL OFFICER Sullivan Patrick William

    4 - HARROW, INC. (0001360214) (Issuer)

    2/2/26 8:21:48 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Sullivan Patrick William

    3 - HARROW, INC. (0001360214) (Issuer)

    2/2/26 8:20:51 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Opaleye Management Inc. sold $1,066,914 worth of shares (20,000 units at $53.35) (SEC Form 4)

    4 - HARROW, INC. (0001360214) (Issuer)

    1/8/26 4:05:20 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Opaleye Management Inc. bought $199,400 worth of shares (20,000 units at $9.97) (SEC Form 4)

    4 - HARROW, INC. (0001360214) (Issuer)

    4/25/24 5:19:24 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opaleye Management Inc. bought $204,640 worth of shares (20,000 units at $10.23) (SEC Form 4)

    4 - HARROW, INC. (0001360214) (Issuer)

    4/24/24 4:40:20 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opaleye Management Inc. bought $310,390 worth of shares (29,400 units at $10.56) (SEC Form 4)

    4 - HARROW, INC. (0001360214) (Issuer)

    4/19/24 6:24:32 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Harrow with a new price target

    Cantor Fitzgerald initiated coverage of Harrow with a rating of Overweight and set a new price target of $76.00

    7/11/25 8:12:59 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Harrow with a new price target

    BTIG Research initiated coverage of Harrow with a rating of Buy and set a new price target of $62.00

    6/12/25 7:54:43 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Harrow

    William Blair initiated coverage of Harrow with a rating of Outperform

    6/10/25 8:09:06 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    Leadership Updates

    Live Leadership Updates

    View All

    Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

    Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Mike Biega has joined Harrow as Vice President of Investor Relations and Communications, succeeding Jamie Webb, Director of Communications and Investor Relations, who recently announced her retirement. Jamie will remain in her role into August to support a smooth and effective transition. "We are excited to welcome Mike to the Harrow Family. His wealth of experience in investor relations and strategic communications will be a tremendous asset as we pursue our objective of becoming the leading U.S. ophthalmic pharmaceutical company," said Mark L. Baum, Chief Executive Officer of Harrow. "I a

    6/18/25 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

    Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Amir H. Shojaei, PharmD, PhD, has joined Harrow as Chief Scientific Officer (CSO). With a remarkable career spanning 28 years in life sciences, Dr. Shojaei brings deep expertise in clinical development, regulatory affairs, and the commercialization of biopharmaceutical and biologic products, including groundbreaking work in anterior and posterior segment ophthalmic indications. Dr. Shojaei most recently served as CSO and Executive Vice President of Clinical Development at AsclepiX Therapeutics, where he spearheaded the development of innovative therapies for neovascular retinal disorders. P

    1/7/25 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial

    Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately. DiPasquale will oversee sales, marketing, and sales operations for Harrow's rapidly growing portfolio of branded ophthalmic products. This new role reflects Harrow's commitment to enhancing its leadership structure to support the Company's continued growth. John Saharek, Harrow's Chief Commercial Officer and Chief Executive Officer of ImprimisRx, will continue to oversee Harrow's commercial business, focusing on the day-to-day management of Harrow's market‑leading compounded division. DiPasquale

    5/13/24 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Harrow Inc.

    SC 13G/A - HARROW, INC. (0001360214) (Subject)

    12/5/24 7:08:52 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Harrow Inc.

    SC 13G/A - HARROW, INC. (0001360214) (Subject)

    10/8/24 6:41:41 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Harrow Inc. (Amendment)

    SC 13G/A - HARROW, INC. (0001360214) (Subject)

    2/13/24 5:25:53 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    Financials

    Live finance-specific insights

    View All

    Harrow Announces Third Quarter 2025 Financial Results

    Third-Quarter 2025 and Recent Selected Highlights:  Total revenues of $71.6 million, a 45% increase over $49.3 million recorded in the prior-year periodGAAP net income of $1.0 millionAdjusted EBITDA of $22.7 millionCash and cash equivalents of $74.3 million as of September 30, 2025 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the third quarter ended September 30, 2025. The Company also posted its third quarter Letter to Stockholders and corporate presentation to the "Inve

    11/10/25 4:05:00 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025

    NASHVILLE, Tenn., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the third quarter ended September 30, 2025, on Monday, November 10, 2025, after the market close. The Company will also post its third quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, November 11, 2025, to discuss the results and provide a business update. Conference Call InformationParticipants can access the live webcast of Harrow's presentation on t

    10/27/25 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Announces Second-Quarter 2025 Financial Results

    Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year periodGAAP net income of $5.0 millionAdjusted EBITDA of $17.0 millionCash and cash equivalents of $53.0 million as of June 30, 2025 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the second quarter ended June 30, 2025. The Company also posted its second quarter Letter to Stockholders and corporate presentation to the "Investors" s

    8/11/25 4:01:00 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care